News Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.92 ^USD	-2.10%		+1.10%	+3.49%

May. 22	Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines	MT
May. 22	Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	May. 24	PU
Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines	May. 22	MT
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	May. 22	AQ
Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	May. 22	CI
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	May. 20	AQ
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	May. 17	AQ
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 08	AQ
Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	Apr. 05	MT
Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	Apr. 05	MT
ADRs Close Lower; Moatable Inc. Declines 33.3%	Apr. 04	DJ
Syncona notes investee Achilles's annual loss narrows	Apr. 04	AN
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights	Apr. 04	AQ
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 04	CI
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	Apr. 04	AQ
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	Apr. 04	CI
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference	Feb. 05	AQ
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction	Dec. 18	AQ
BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50	Dec. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Summary

Filters